India Tops China As Preferred Site Of Outsourced Clinical Trials
This article was originally published in PharmAsia News
India has surpassed China as the country preferred by foreign drug makers for conducting clinical trials. India's Planning Commission says the country received 139 new trials over a recent period when China received 98. The commission said the outsourced trials are worth about $300 million to the country and the amount is expected to grow to as much as $2 billion within two years. The same report noted, however, that India is short 30,000 to 50,000 research personnel needed to carry out the trials. (Click here for more
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.
Increasing number of product development meetings suggests that many complex generics remain in the development stages.